Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study
10.1186/s40880-017-0229-0
- Author:
Li YA-JUN
1
;
Yi PING-YONG
;
Li JI-WEI
;
Liu XIAN-LING
;
Tang TIAN
;
Zhang PEI-YING
;
Jiang WEN-QI
Author Information
1. Department of Lymphoma and Hematology
- Keywords:
ABO blood type;
Extranodal natural killer/T-cell lymphoma;
Prognosis;
The International Prognostic Index;
The Korean Prognostic Index
- From:Chinese Journal of Cancer
2017;36(9):427-437
- CountryChina
- Language:Chinese
-
Abstract:
Background:The prognostic significance of ABO blood type for lymphoma is largely unknown.We evaluated the prognostic role of ABO blood type in patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL).Methods:We retrospectively analyzed clinical data of 697 patients with newly diagnosed ENKTL from three cancer centers.The prognostic value of ABO blood type was evaluated using Kaplan-Meier curves and Cox proportional hazard models.The prognostic values of the International Prognostic Index (IPI) and the Korean Prognostic Index (KPI) were also evaluated.Results:Compared with patients with blood type O,those with blood type non-O tended to display elevated baseline serum C-reactive protein levels (P =0.038),lower rate of complete remission (P =0.005),shorter progression-free survival (PFS,P ＜ 0.001),and shorter overall survival (OS,P =0.001).Patients with blood type O/AB had longer PFS (P ＜ 0.001) and OS (P =0.001) compared with those with blood type A/B.Multivariate analysis demonstrated that age ＞60 years (P ＜ 0.001),mass ＞5 cm (P =0.001),stage Ⅲ/Ⅳ (P ＜ 0.001),elevated serum lactate dehydrogenase (LDH) levels (P =0.001),and blood type non-O were independent adverse predictors of OS (P =0.001).ABO blood type was found to be superior to both the IPI in discriminating patients with different outcomes in the IPI low-risk group and the KPI in distinguishing between the intermediate-to-low-and high-to-intermediate-risk groups.Conclusions:ABO blood type was an independent predictor of clinical outcome for patients with ENKTL.
